Precision Medicine for Your Practice: Interpreting Results from Somatic Cancer Panels (CME)
Self-paced • 0.5 credits
About this Course
Precision Medicine for Your Practice is a series of short (20-30 min), online modules covering specific topics in genomics and precision medicine. In this module, Interpreting Results from Somatic Cancer Panel Testing, participants will learn how to find and use important information on somatic cancer testing panel reports. What are the key components of a test report? What do specific findings mean? Learn how to identify important test characteristics to compare and contrast offerings from different labs, find actionable information on the test report, and interpret results in the context of the individual patient using the five parts of this module: overview information via an animated video; practice cases to facilitate learning-by-doing; "dig deeper" for more in-depth topics; and logistics and additional resources for more detail.
Release Date: June 6, 2017 Renewal Date: June 4, 2020 Expiration Date: June 4, 2023
Upon completion of this educational activity, the learner will be able to:
Identify important test characteristics to compare and contrast offerings from different labs
Find actionable information on the report
Interpret results in the context of the individual patient
Statement of Need
Genetic technology is rapidly expanding, often too quickly for physicians and other health professionals to become familiar with new technologies before their patients inquire about them, and too quickly for adequate evidence regarding the clinical utility of the technologies to be produced. This educational module will assist physicians and health professionals to determine when somatic cancer panel testing is appropriate for their patients and how to interpret the results of such testing.
Statement of Competency
This activity is designed to address the following ABMS/ACGME competencies: patient care, medical knowledge, and interpersonal and communication skills.
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
The American Medical Association designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Claiming Your CME Credit
In order to claim AMA PRA Category 1 Credit™, you must: 1) answer the pre-assessment questions, 2) work through the module in its entirety, 3) successfully complete the post-assessment by answering 2 out of 3 questions correctly and 4) complete the evaluation.
Barry D. Dickinson, PhD, CME Program Committee, AMA
Abdallah Elias, MD, Department of Medical Genetics, Shodair Children's Hospital
Jeanette McCarthy, MPH, PhD, Visiting Associate Professor, Division of Medical Genetics, UCSF School of Medicine
Laura Nicholson, MD, Co-Director of Education, Scripps Translational Science Institute
James O'Leary, MBA, Chief innovation Officer, Genetic Alliance
Janet K. Williams, PhD, RN, FAAN, Professor of Nursing, Chair of Behavioral and Social Science Research, University of Iowa
Barry D. Dickinson, PhD, CME Program Committee, AMA (Content Reviewer)
Emily Edelman, MS, CGC, Associate Director, Clinical and Continuing Education, The Jackson Laboratory (Author)
Abdallah Elias, MD, Department of Medical Genetics, Shodair Children's Hospital (Content Reviewer)
Marilyn J. Heine, MD, Hematologist/Oncologists, Regional Hematology Oncology Associates (Content Consultant)
Therese Ingram Nissen, MA, Senior Instructional Designer/Technologist, The Jackson Laboratory (Author)
Katie Johansen Taber, PhD, Principal Policy Analyst, Science and Biotechnology, AMA (Author)
Barbara L. McAneny, MD, CEO, New Mexico Oncology Hematology Consultants (Content Consultant)
Laura Nicholson, MD, Co-Director of Education, Scripps Translational Science Institute (Author)
James O'Leary, MBA, Chief innovation Officer, Genetic Alliance (Content Reviewer)
Kate Reed, MPH, ScM, CGC, Director, Clinical and Continuing Education, The Jackson Laboratory (Author)
Suzanna Schott, ScM, CGC, Medical Writer, The Jackson Laboratory (Author)
In order to assure the highest quality of certified CME programming, and to comply with the ACCME Standards for Commercial Support, the AMA requires that all faculty, planners and members of the AMA CME Program Committee disclose relevant financial relationships with any commercial or proprietary entity producing health care goods or services relevant to the content being planned or presented. The following disclosures are provided:
Barbara L. McAneny, MD, CEO of Innovative Oncology Business Solutions, and CEO or New Mexico Hematology Oncology Consultants Ltd
Jeanette McCarthy, PhD, MPH, Consultant to Big Science Media, Omicia, and Precision Medicine Advisors
Suzanna Schott, ScM, CGC, Stockholder of Merck, Amgen, and Teva
Janet K. Williams, PhD, RN, FAAN, Stockholder of Pfizer
No other planners or faculty have relevant financial relationships to disclose.